Trust Signals
Written by: FormBlends Medical Team. Reviewed against primary literature on PubMed, FDA compounding guidance, and the WADA Prohibited List (2024 edition).
Last updated: 2026-05-29. No affiliate relationships with any clinic listed or referenced. Evidence grades assigned using a modified GRADE framework.
Scope: This page covers how to find, evaluate, and safely use a peptide therapy clinic in the United States. It does not constitute medical advice.
Key Takeaways
- Only semaglutide and tirzepatide among commonly prescribed clinic peptides have Phase 3 RCT evidence in large human populations. Every other peptide offered at most clinics has moderate-to-very-low human evidence.
- A legitimate peptide therapy clinic requires a licensed prescriber, a 503A or 503B compounding pharmacy partner, baseline bloodwork, and a certificate of analysis (COA) for each peptide batch.
- Telehealth peptide clinics are legal and increasingly common, but they cannot perform physical examination, which matters for higher-risk protocols.
- WADA prohibits growth hormone releasing peptides (GHRPs) and growth hormone releasing hormone analogues (GHRHs) in competitive sport regardless of prescription status.
- Peptide degradation begins at room temperature within hours for most injectable preparations. How a clinic stores and ships product is a direct quality indicator.
What Are Peptide Therapy Clinics and Who Actually Uses Them?
Peptide therapy clinics are medical practices, either in-person or telehealth, where a licensed provider prescribes compounded peptides for specific health goals including weight loss, recovery, hormonal optimization, and sexual health. Most patients are adults aged 30 to 60 who are not well served by standard-of-care options or who want access to compounds not available as commercial drugs. The clinics range from single-physician integrative practices to large direct-to-consumer telehealth platforms serving tens of thousands of patients.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Direct Answer: What Does a Peptide Therapy Clinic Do?
A peptide therapy clinic evaluates your health history, orders relevant labs, and then prescribes compounded peptide injections or oral preparations tailored to your goals. The provider monitors your response over time and adjusts dosing. The clinic is the prescriber and often the coordinator; a licensed compounding pharmacy is the manufacturer. You are not buying supplements; you are filling a prescription for a compounded drug.
Table of Contents
- What do peptide therapy clinics actually prescribe?
- Evidence ledger: confidence grades for common clinic peptides
- How the mechanism works, with real numbers
- What most pages get wrong about peptide clinics
- Is a peptide clinic legal, and what makes one compliant?
- How to vet a clinic: operational checklist and label literacy
- Telehealth vs in-person peptide clinics: honest head-to-head
- The chemistry behind storage rules
- Cost and insurance reality
- FAQ
- Sources
What Do Peptide Therapy Clinics Actually Prescribe?
The most commonly prescribed categories across US peptide clinics as of 2025 to 2026 are:
| Peptide | Category | Route | Primary Stated Use | FDA Status |
|---|---|---|---|---|
| Semaglutide (compounded) | GLP-1 agonist | SubQ injection | Weight loss, glycemic control | Approved drug; compounded versions under shortage rules |
| Tirzepatide (compounded) | GLP-1/GIP dual agonist | SubQ injection | Weight loss | Approved drug; compounded versions under shortage rules |
| CJC-1295 + Ipamorelin | GHRH analogue + GHRP | SubQ injection | GH pulse amplification, body composition | Not approved; compounded off-label |
| BPC-157 | Pentadecapeptide | SubQ or oral | Tissue repair, gut healing | Not approved; compounded off-label |
| TB-500 (Thymosin Beta-4 fragment) | Actin-sequestering peptide fragment | SubQ injection | Recovery, anti-inflammatory | Not approved; compounded off-label |
| PT-141 (Bremelanotide) | Melanocortin receptor agonist | SubQ or intranasal | Sexual dysfunction | Approved as Vyleesi (hypoactive desire in women); compounded off-label in men |
| Sermorelin | GHRH analogue | SubQ injection | GH stimulation, anti-aging | Previously approved; now compounded |
Evidence Ledger: Confidence Grades for Common Clinic Peptides
| Peptide | Best Available Evidence | Effect Direction | Confidence (GRADE-style) | Key Honest Caveat |
|---|---|---|---|---|
| Semaglutide | Multiple Phase 3 RCTs (STEP trials, thousands of participants) | Positive for weight loss and glycemic control | High | Approved-drug evidence does not automatically apply to compounded formulations |
| Tirzepatide | Phase 3 RCTs (SURMOUNT program) | Positive for weight loss | High | Same compounding caveat; shortage-based prescribing rules may shift |
| CJC-1295 | Small human studies (e.g., Teichman et al., 2006, n=65) showing GH pulse increase | Positive for acute GH elevation | Moderate | GH elevation does not prove body composition outcomes at clinical doses |
| Ipamorelin | Human PK studies; animal efficacy data | Positive for GH secretion | Low | No long-term human RCT on clinical endpoints |
| BPC-157 | Animal models, in-vitro; no published human RCTs as of 2026 | Positive in animal tissue repair models | Very Low | Animal-to-human translation of dose and effect is unvalidated |
| TB-500 (Thymosin Beta-4 frag.) | In-vitro and animal data only | Directionally positive in animal wound/cardiac models | Very Low | No human clinical trials; mechanism plausible but unproven at human scale |
| PT-141 | Phase 2 and 3 RCTs supporting FDA approval in women (Vyleesi) | Positive for female hypoactive sexual desire | Moderate to High (women); Low (men, off-label) | Male use is extrapolated from mechanism; not from RCT data in men |
| Sermorelin | Historical human studies; older approval dossier data | Positive for GH stimulation | Low to Moderate | Evidence base is dated; long-term clinical outcome data limited |
How the Mechanism Works, With Real Numbers
GLP-1 agonists (semaglutide, tirzepatide): These peptides bind GLP-1 receptors in the pancreas, hypothalamus, and gut. Semaglutide has a half-life of approximately 7 days due to albumin binding and a C-18 fatty-acid side chain. In the STEP 1 trial (Wilding et al., 2021, n=1961), once-weekly 2.4 mg semaglutide produced a mean 14.9% body-weight reduction over 68 weeks versus 2.4% with placebo. The mechanism is delayed gastric emptying plus central appetite suppression via hypothalamic GLP-1R signaling. What this does NOT prove: that compounded semaglutide at variable purity achieves identical pharmacokinetics.
Growth hormone secretagogues (CJC-1295, ipamorelin): CJC-1295 with DAC (drug affinity complex) binds GHRH receptors on pituitary somatotrophs, extending the half-life to roughly 6 to 8 days (Teichman et al., 2006). Ipamorelin is a selective GHRP that binds the ghrelin receptor (GHS-R1a) with minimal cortisol or prolactin spillover compared to older GHRPs like GHRP-6. Combined use amplifies GH pulse height and area under the curve. The specific downstream effect on lean mass or fat loss in middle-aged adults without GH deficiency is not robustly quantified in human RCTs.
BPC-157: The proposed mechanism involves upregulation of growth factor signaling (including VEGF and PDGF pathways) and modulation of the nitric oxide system. Animal studies use intraperitoneal doses in the microgram-per-kilogram range, but no dose-response curve in humans has been published. Treating a rodent finding as a human dose guide is an unjustified extrapolation.
What Most Pages Get Wrong About Peptide Therapy Clinics
The compounding pharmacy gap is the real quality story. Nearly every peptide clinic review focuses on the practitioner credentials and protocol. Almost none explain that the actual drug product quality depends on the compounding pharmacy, not the clinic. A clinic can employ a board-certified physician and still dispense a peptide with 70% of label potency if sourced from a low-quality compounder. Here is what to verify:
- Is the pharmacy 503A or 503B registered? (Search the FDA's 503B outsourcing facility list, publicly available at fda.gov.)
- Does the COA show identity confirmation by HPLC or mass spectrometry, not just appearance?
- Is sterility and endotoxin testing documented for injectables? Endotoxin contamination causes fever and inflammatory responses independent of the peptide itself.
- Does the COA come from an independent third-party laboratory, or just the compounder's own in-house testing?
Many telehealth peptide clinics advertise "pharmaceutical grade" without specifying which of these criteria are met. That phrase has no regulatory definition.
Is a Peptide Clinic Legal, and What Makes One Compliant?
Prescribing compounded peptides in the United States is legal when a licensed practitioner issues a valid prescription for an identified patient (503A pathway) or when an outsourcing facility produces batches under cGMP (503B pathway). The FDA has regulatory authority over compounding pharmacies under the Drug Quality and Security Act of 2013.
Where clinics run into legal risk: prescribing peptides that the FDA has placed on its Category 2 list (substances that may not be compounded for office use) or sourcing active pharmaceutical ingredients from non-FDA-registered suppliers. As of 2025, the FDA has taken enforcement action against clinics and pharmacies compounding BPC-157 for injection, citing it as a non-bulk drug substance. The regulatory landscape for specific peptides shifts year to year; a compliant clinic monitors FDA guidance actively.
Selling any peptide labeled "for research only" directly to consumers for human use is not a legal workaround. The intended use, not the label, determines FDA jurisdiction.
How to Vet a Clinic: Operational Checklist and Label Literacy
Use this checklist when evaluating any peptide therapy clinic:
| Checkpoint | What to Ask or Verify | Why It Matters |
|---|---|---|
| Licensed prescriber | Name, license type (MD/DO/NP/PA), and state license number verifiable on state board website | Prescriptions from unlicensed entities are not valid |
| Compounding pharmacy identity | Name and 503A or 503B registration status; check fda.gov outsourcing facility list | 503B facilities face cGMP-level oversight; 503A varies by state |
| COA availability | Request a current lot COA before purchasing; it should include HPLC identity, purity (greater than 98% for injectables), potency, sterility, and endotoxin | No COA means no quality verification |
| Baseline labs required | At minimum: comprehensive metabolic panel, CBC, relevant hormone levels (IGF-1 for GH protocols, HbA1c for GLP-1) | Prescribing without baseline labs is clinically and legally risky |
| Informed consent | Written consent referencing off-label status for non-approved compounds | Required for off-label prescribing of compounded drugs |
| Cold-chain shipping | Insulated packaging with ice packs; ask about handling in transit | Most peptides degrade meaningfully above 8 degrees Celsius over time |
| No outcome guarantees | Any clinic promising specific weight loss or muscle gain numbers is overclaiming | Outcome variation is large; guarantees signal marketing over medicine |
Telehealth vs In-Person Peptide Clinics: Honest Head-to-Head
| Factor | Telehealth Peptide Clinic | In-Person Peptide Clinic | Winner |
|---|---|---|---|
| Access and convenience | Available in most states; no travel | Limited to local geography | Telehealth |
| Cost | Generally lower overhead; often $50 to $150 less per month | Higher overhead passed to patient | Telehealth |
| Physical examination | Not possible | Full exam feasible | In-person |
| Injection training | Video-only; reliant on patient self-teaching | In-person nurse or provider can supervise first injections | In-person |
| Monitoring frequency | Typically labs by mail-in kit; follow-up by message or video | Can draw labs and adjust same visit | In-person |
| Appropriate for GLP-1 protocols | Yes; low procedural complexity | Yes | Tie |
| Appropriate for novel/higher-risk peptides | Marginal; limited safety net | Preferable | In-person |
| Quality of care ceiling | Depends heavily on platform rigor | Depends on clinic; ceiling is higher when exam is feasible | In-person (narrow) |
The Chemistry Behind Storage Rules
Peptides are short amino-acid chains held together by peptide bonds. Two degradation pathways matter in practice.
Hydrolysis: Water molecules attack the peptide bond, cleaving the chain. This reaction accelerates with temperature. A peptide stable for months at 2 to 8 degrees Celsius can lose meaningful potency in days at room temperature (roughly 20 to 25 degrees Celsius) once reconstituted in aqueous solution. Lyophilized (freeze-dried) powder is far more stable because it removes the water needed for hydrolysis. When a clinic ships reconstituted solution rather than lyophilized powder, you are receiving a product already on the degradation clock.
Oxidation: Methionine and cysteine residues within a peptide chain are susceptible to oxidation by dissolved oxygen. This is why high-quality compounders use bacteriostatic water (which contains benzyl alcohol, an antimicrobial) rather than plain sterile water, and why vials are often nitrogen-purged or sealed under minimal headspace. If your reconstituted peptide looks cloudy or has visible particulate, that is a degradation signal, not a solubility issue to push through.
This chemistry is why the rule "store refrigerated, use within the stated window" is not arbitrary. It is a direct consequence of reaction kinetics at biological temperatures. A clinic that ships product via standard ground shipping in July without cold packs is delivering a degraded product regardless of the COA on the day it left the pharmacy.
Cost and Insurance Reality
Peptide therapy is almost never covered by insurance when obtained through a compounding pharmacy, because compounded drugs do not have National Drug Codes required for pharmacy benefit adjudication. The one exception is when a branded approved drug (Ozempic, Wegovy, Mounjaro, Zepbound) is prescribed and covered; that happens through standard pharmacy channels, not peptide clinics.
Rough monthly cost ranges for clinic-based compounded peptides in 2025 to 2026: GLP-1 programs run approximately $200 to $500 per month depending on dose and clinic markup. GH secretagogue stacks (CJC-1295 plus ipamorelin) typically run $150 to $400 per month. BPC-157 protocols run $100 to $250 per month. These figures exclude the initial consultation fee, which at many clinics is $100 to $300. Some clinics bundle labs and peptides into monthly membership models ranging from $300 to $800 per month all-in. Direct comparison of value requires knowing the compounding pharmacy, the COA quality, and the practitioner monitoring frequency, not just the price.
FAQ
What do peptide therapy clinics actually prescribe?
Most prescribe compounded peptides such as semaglutide, tirzepatide, BPC-157, TB-500, CJC-1295, ipamorelin, and PT-141. Only semaglutide and tirzepatide have FDA-approved finished-drug equivalents. The others are prescribed as compounded research preparations under practitioner supervision.
Are peptide therapy clinics legal in the United States?
Yes, when a licensed practitioner writes a valid prescription and a licensed 503A or 503B compounding pharmacy fills it. Selling peptides as supplements or research chemicals without a prescription is not legal for human use under FDA rules.
How much does peptide therapy cost at a clinic?
Costs vary widely. GLP-1 programs (compounded semaglutide) run roughly $200 to $500 per month depending on dose and clinic. Growth hormone secretagogue protocols such as CJC-1295 plus ipamorelin typically cost $150 to $400 per month. Rarely covered by insurance.
What should I look for in a reputable peptide therapy clinic?
Look for a licensed prescribing provider (MD, DO, NP, or PA), use of an FDA-registered 503A or 503B compounding pharmacy, provision of a certificate of analysis (COA) for each batch, required baseline labs, and no guarantees of specific outcomes.
Can I do peptide therapy without going to a clinic in person?
Many clinics now operate as telehealth platforms. You complete a medical intake, consult with a provider via video, and receive compounded peptides by mail from the clinic's partner pharmacy. In-person clinics remain preferable for anything requiring physical examination.
What is the difference between a 503A and 503B compounding pharmacy?
A 503A pharmacy compounds for individual patient prescriptions and is regulated primarily by state boards. A 503B outsourcing facility compounds larger batches under cGMP standards similar to drug manufacturers and is registered with the FDA, offering a higher quality assurance baseline.
How do I read a certificate of analysis for a compounded peptide?
Check that identity (HPLC or mass spec), purity (greater than 98% is typical for injectable-grade peptides), potency (within 90 to 110% of label claim), sterility, and endotoxin results are all listed and passing. A COA without an independent third-party lab name is not meaningful.
Which peptides have the strongest human clinical evidence?
Semaglutide and tirzepatide have the strongest evidence: large Phase 3 RCTs in thousands of patients. Growth hormone secretagogues such as CJC-1295 have small human studies showing GH pulse elevation. BPC-157 and TB-500 have only animal and in-vitro data in humans as of 2026.
What are the biggest red flags at a peptide clinic?
No licensed prescriber on staff, no baseline labs required, no COA available on request, peptides sold as supplements rather than prescribed, and guaranteed outcome claims are all serious red flags. Clinics sourcing from non-pharmacy chemical suppliers are operating outside legal frameworks.
Is BPC-157 approved or safe for human use?
BPC-157 is not FDA-approved for any indication. Human safety data are very limited. It is compounded and prescribed off-label by some clinics. Animal data suggest tissue-healing effects, but translating animal dosing to humans is not validated. Use involves meaningful uncertainty.
How do telehealth peptide clinics compare to in-person clinics?
Telehealth clinics offer lower cost and convenience and are appropriate for well-defined protocols like GLP-1 therapy. In-person clinics allow physical exam, injection training, and closer monitoring, which matters more for novel or higher-risk peptide protocols.
Will peptide therapy show up on a drug test?
GLP-1 agonists are not on standard workplace drug panels. However, WADA prohibits growth hormone releasing peptides and growth hormone secretagogues in competitive sport. Athletes subject to anti-doping rules should review the current WADA Prohibited List before starting any secretagogue protocol.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. (STEP 1 trial)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1 trial)
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC-157. Current Medicinal Chemistry. 2012;19(1):126-132. (Animal/preclinical data on BPC-157)
- Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of bremelanotide (PT-141) in premenopausal women with hypoactive sexual desire disorder. Menopause. 2014;21(6):611-617.
- US Food and Drug Administration. Drug Quality and Security Act (DQSA), Public Law 113-54. 2013. Available at fda.gov.
- US Food and Drug Administration. 503B outsourcing facility list. Available at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. Accessed 2026.
- World Anti-Doping Agency. Prohibited List 2024. S2: Peptide hormones, growth factors, related substances, and mimetics. Available at wada-ama.org.
- US Pharmacopeia. USP General Chapter 797: Pharmaceutical compounding, sterile preparations. 2023 revision.
- US Food and Drug Administration. Guidance for industry: Compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 2018.
Footer Disclaimers
Platform disclaimer: FormBlends is an informational platform. FormBlends does not prescribe, dispense, or manufacture any peptide, drug, or supplement. Nothing on this page constitutes medical advice. Consult a licensed healthcare provider before beginning any peptide or hormonal therapy.
Research compound and compounded medication disclaimer: Many peptides discussed on this page are not FDA-approved drugs. They may be prescribed as compounded medications by licensed practitioners. Compounded drugs are not FDA-approved and have not been evaluated for safety, efficacy, or quality by the FDA. The regulatory status of specific compounds may change; verify current status with a licensed provider or pharmacist.
Results disclaimer: Individual responses to peptide therapy vary substantially. No outcome described on this page is guaranteed. Evidence grades reflect the quality of published literature, not a prediction of personal results.
Trademark disclaimer: Ozempic, Wegovy, Mounjaro, Zepbound, and Vyleesi are registered trademarks of their respective manufacturers. FormBlends has no affiliation with any of these companies. Brand names are used for identification purposes only.